OPK-88004

OPK-88004 is an androgen receptor antagonist that is currently under development by Opko Health. It is being investigated for its potential use in the treatment of prostate cancer and benign prostatic hyperplasia (BPH).

Mechanism of Action[edit | edit source]

OPK-88004 works by binding to the androgen receptor, thereby inhibiting the action of androgens, such as testosterone and dihydrotestosterone. This mechanism of action is similar to that of other androgen receptor antagonists, such as enzalutamide and apalutamide.

Clinical Trials[edit | edit source]

As of 2021, OPK-88004 is in Phase 2 clinical trials for the treatment of prostate cancer and BPH. The trials are being conducted by Opko Health, a multinational pharmaceutical and diagnostics company.

Potential Applications[edit | edit source]

If successful in clinical trials, OPK-88004 could be used in the treatment of prostate cancer and BPH. It may also have potential applications in the treatment of other conditions that are influenced by androgens, such as hirsutism and acne.

See Also[edit | edit source]

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

40px

This Prostate cancer-related article is a stub. You can help WikiMD by expanding it.

This BPH related article is a stub. You can help WikiMD by expanding it.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.